Diagonal Bio

0.00 SEK

0.00 %

Less than 1K followers

DIABIO

Nordic SME

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

0.00 %

-20.00 %

-50.00 %

-63.64 %

-62.93 %

-73.01 %

-98.83 %

-

-99.89 %

Diagonal Bio operates in biotechnology. The company develops a platform for detecting and diagnosing small sections of pathogen genomes, such as viruses, bacteria and fungi. In addition to its main business, it also offers service and related ancillary services. Diagonal Bio's operations are operated with the largest presence in Sweden. The company was founded in 2020 and is headquartered in Lund.

Market cap

6.56M SEK

Turnover

12.14K SEK

Revenue

60K

EBIT %

-15,700 %

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

27/2

2026

Annual report '25

18/5

2026

Interim report Q1'26

19/5

2026

General meeting '26

All

Press releases

3rd party

ShowingAll content types

Regulatory press release12/1/2025, 7:30 AM

Nomination Committee appointed for Diagonal Bio

Press release11/4/2025, 8:30 AM

Untersteiner Racing signs agreement for a pilot test

Regulatory press release10/31/2025, 7:00 AM

Diagonal Bio publishes interim report for the third quarter of 2025

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Press release10/13/2025, 7:00 AM

Diagonal Bio launches new website to reflect commercial focus on the Animal Health segment

Press release10/3/2025, 9:30 AM

Diagonal Bio initiates collaboration with SVA on evaluation of coronavirus in horses

Regulatory press release9/23/2025, 9:15 AM

Diagonal Bio expands horse testing panel to detect Equine Herpesvirus type 2

Regulatory press release9/18/2025, 11:00 AM

Diagonal Bio receives order from Stall Courant

Regulatory press release8/22/2025, 6:00 AM

Diagonal Bio publishes interim report for the second quarter of 2025

Press release8/20/2025, 6:00 AM

Diagonal Bio AB receives patent approval in Japan

Press release7/7/2025, 11:00 AM

Diagonal Bio AB files patent application for Novel Computational Method that significantly improves LAMP primer design

Regulatory press release6/25/2025, 11:00 AM

The Board of Directors of Diagonal Bio carries out a directed issue to underwriters in connection with exercise of warrants of series TO 2

Regulatory press release6/19/2025, 11:40 AM

Diagonal Bio receives SEK 3.6 million through exercise of warrants of series TO 2

Regulatory press release6/17/2025, 4:47 PM

Update regarding large shareholder’s exercise of warrants of series TO 2

Regulatory press release6/17/2025, 6:30 AM

Diagonal Bio expands equine panel with addition of strangles

Regulatory press release6/16/2025, 6:30 AM

Large shareholder exercises warrants of series TO 2

Regulatory press release6/13/2025, 6:00 AM

Last day of trading in Diagonal Bio’s warrants of series TO 2 is 16 June 2025

Press release6/11/2025, 9:30 AM

Diagonal Bio shares progress update on LAMPlify® commercial pilots

Regulatory press release6/9/2025, 12:00 PM

Svea Bank AB invests SEK 0.5 million in Diagonal Bio AB through the exercise of warrants of series TO 2

Regulatory press release6/4/2025, 6:30 AM

The exercise period for Diagonal Bio’s warrants of series TO 2 starts today

Regulatory press release5/20/2025, 12:00 PM

Bulletin from the Annual General Meeting on 20 May 2025 in Diagonal Bio AB

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.